1. Market Research
  2. > Biotechnology
  3. > Genomics Market Trends
  4. > Biomarkers Market by Product , Type , Application & by Disease Indication - Global Forecast to 2020

In this report, the biomarkers market is segmented on the basis of product, type, application, disease indication, and geography. The product segments included in this report are consumables, services, software. The type segments included in this report are safety biomarkers, efficacy biomarkers, and validation biomarkers. The applications segments included in this report are diagnostics development, drug discovery and development, personalized medicine, disease risk assessment, and other applications. The disease indications segments included in this report are cancer, cardiovascular disorders, neurological disorders, immunological disorders, and other diseases.

The geographic segments included in this report are North America, Europe, Asia, and the Rest of the World (RoW).

The growth of this market is mainly driven by increasing healthcare expenditure, increase in R&D spending, increasing utility of biomarkers for diagnostics, increasing number of CROs, the low cost of clinical trials in developing countries, and new initiatives for biomarker research. The high growth potential in emerging markets and the increasing adoption of personalized medicine and companion diagnostics provides new growth opportunities to players in the biomarkers market.

A combination of bottom-up and top-down approaches were used to calculate the market sizes and growth rates of the global biomarkers market and its subsegments. Secondary information was used to identify overall revenue, geographic reach, and product portfolios of market players. Estimates of the biomarkers market segment revenues were validated through primary interviews. Primary interviews with key opinion leaders were also used to determine the percentage shares of each subsegment and the relative differences in growth rates.

The report provides qualitative insights on key market shares, growth rates, and market drivers for important subsegments. It maps the market sizes and growth rates of each segment and identifies segments poised to witness rapid growth. The report includes company profiles and a competitive landscape of the biomarkers market. The company profiles include the financial performances, product portfolios, and developments of each company, whereas, the competitive landscape covers the growth strategies adopted by industry players over the last three years. The report also includes analyses of industry developments such as acquisitions, agreements, collaborations & partnerships; new product launches; and other developments.

Reasons to Buy the Report:

The report will enable both established firms and new entrants to gauge the pulse of the market and make important strategic growth decisions.

The report provides insights on the following:
- Product Development/Innovation: Product portfolios of the top players in the biomarkers market. Detailed insights on upcoming technologies, R&D activities, and new product launches in the biomarkers market
- Competitive Assessment: In-depth assessment of market shares, strategies, geographic and business segments, and product portfolios of the leading players in the biomarkers market
- Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the market for various biomarkers across geographies
- Market Diversification: Exhaustive information about new products, recent developments, and investments in the biomarkers market

Table Of Contents

Biomarkers Market by Product , Type , Application and by Disease Indication - Global Forecast to 2020
TABLE OF CONTENTS

1 INTRODUCTION 17
1.1 OBJECTIVES OF THE STUDY 17
1.2 MARKET DEFINITION 17
1.3 MARKET SCOPE 18
1.3.1 MARKETS COVERED 18
1.3.2 YEARS CONSIDERED IN THE REPORT 19
1.4 CURRENCY 19
1.5 LIMITATIONS 19
1.6 STAKEHOLDERS 19
2 RESEARCH METHODOLOGY 20
2.1 MARKET SIZE ESTIMATION 21
2.2 MARKET BREAKDOWN AND DATA TRIANGULATION 24
2.3 MARKET SHARE ESTIMATION 25
2.3.1 KEY DATA FROM SECONDARY SOURCES 25
2.3.2 KEY DATA FROM PRIMARY SOURCES 25
2.3.3 ASSUMPTIONS FOR THE STUDY 26
3 EXECUTIVE SUMMARY 27
4 PREMIUM INSIGHTS 31
4.1 LUCRATIVE OPPORTUNITIES IN THE GLOBAL BIOMARKERS MARKET 31
4.2 LIFE CYCLE ANALYSIS, BY REGION, 2015 33
5 MARKET OVERVIEW 34
5.1 INTRODUCTION 35
5.2 MARKET SEGMENTATION 35
5.2.1 BY PRODUCT 35
5.2.2 BY TYPE 35
5.2.3 BY APPLICATION 36
5.2.4 BY DISEASE INDICATION 36
5.3 MARKET DYNAMICS 37
5.3.1 DRIVERS 38
5.3.1.1 Increasing healthcare expenditure 38
5.3.1.2 Growth in RandD funding 38
5.3.1.3 Increasing utility of biomarkers for diagnostic purposes 39
5.3.1.4 Rising number of CROs and low cost for conducting clinical trials in developing countries 40
5.3.1.5 High prevalence of cancer 40
5.3.1.6 New initiatives for biomarker research 41
5.3.2 RESTRAINTS 42
5.3.2.1 High capital investment and low benefit-cost ratio 42
5.3.2.2 Poorly suited regulatory and reimbursement systems 42
5.3.2.3 High cost of tests 43
5.3.2.4 Technical issues related to sample collection and storage 43
5.3.3 OPPORTUNITIES 44
5.3.3.1 Personalized medicine 44
5.3.3.2 Companion diagnostics 45
5.3.3.3 Emerging economies 45
5.3.4 CHALLENGES 46
5.3.4.1 Proving clinical validity and utility of biomarker-based tests 46
6 BIOMARKERS MARKET, BY PRODUCTS 48
6.1 INTRODUCTION 49
6.2 CONSUMABLES 50
6.3 SERVICES 52
6.4 SOFTWARE 54
7 BIOMARKERS MARKET, BY TYPE 56
7.1 INTRODUCTION 57
7.2 SAFETY BIOMARKERS 58
7.3 EFFICACY BIOMARKERS 60
7.3.1 PREDICTIVE BIOMARKERS 63
7.3.2 SURROGATE BIOMARKERS 64
7.3.3 PHARMACODYNAMIC BIOMARKERS 66
7.3.4 PROGNOSTIC BIOMARKERS 67
7.4 VALIDATION BIOMARKERS 69
8 BIOMARKERS MARKET, BY APPLICATION 71
8.1 INTRODUCTION 72
8.2 DIAGNOSTICS DEVELOPMENT 73
8.3 DRUG DISCOVERY AND DEVELOPMENT 75
8.4 PERSONALIZED MEDICINE 77
8.5 DISEASE RISK ASSESSMENT 78
8.6 OTHER APPLICATIONS 80
9 BIOMARKERS MARKET, BY DISEASE INDICATION 82
9.1 INTRODUCTION 83
9.2 CANCER 84
9.3 CARDIOVASCULAR DISORDERS 86
9.4 NEUROLOGICAL DISORDERS 88
9.5 IMMUNOLOGICAL DISORDERS 90
9.6 OTHER DISEASES 92
10 BIOMARKERS MARKET, BY REGION 95
10.1 INTRODUCTION 96
10.2 NORTH AMERICA 99
10.2.1 U.S. 106
10.2.2 CANADA 112
10.3 EUROPE 118
10.4 ASIA 124
10.5 REST OF THE WORLD (ROW) 131
11 COMPETITIVE LANDSCAPE 137
11.1 INTRODUCTION 137
11.2 STRATEGIC OVERVIEW 137
11.3 MARKET SHARE ANALYSIS, BIOMARKERS MARKET 139
11.4 COMPETITIVE SITUATION AND TRENDS 140
11.4.1 ACQUISITIONS 141
11.4.2 AGREEMENTS, COLLABORATIONS, EXPANSION, JOINT VENTURES, AND PARTNERSHIPS 142
11.4.3 NEW PRODUCT AND SERVICE LAUNCHES 143
11.4.4 OTHER DEVELOPMENTS 144
12 COMPANY PROFILES 145
(Overview, Financials, Products and Services, Strategy, and Developments)*
12.1 INTRODUCTION 145
12.2 QIAGEN N.V. 146
12.3 PERKINELMER, INC. 149
12.4 MERCK and CO, INC. 152
12.5 BIO-RAD LABORATORIES, INC. 154
12.6 ENZO BIOCHEM, INC. 156
12.7 EKF DIAGNOSTICS HOLDINGS, INC. 159
12.8 MESO SCALE DIAGNOSTICS, LLC. 162
12.9 SINGULEX, INC. 164
12.10 BIOSIMS TECHNOLOGIES 166
12.11 CISBIO BIOASSAYS 168
12.12 SIGNOSIS, INC. 170

*Details on Financials, Product and Services, Strategy, and Developments might not be captured in case of unlisted companies.

13 APPENDIX 172
13.1 INSIGHTS OF INDUSTRY EXPERTS 172
13.2 DISCUSSION GUIDE 173
13.3 OTHER DEVELOPMENTS 175
13.4 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 179
13.5 AVAILABLE CUSTOMIZATIONS 180
13.6 RELATED REPORTS 181


LIST OF TABLES

TABLE 1 BIOMARKERS MARKET SNAPSHOT 27
TABLE 2 INCREASING HEALTHCARE EXPENDITURE IS PROPELLING THE GROWTH OF BIOMARKERS MARKET 41
TABLE 3 POORLY SUITED REGULATORY AND REIMBURSEMENT SYSTEMS—AN ENTRY BARRIER FOR NEW ENTRANTS 44
TABLE 4 LIST OF FDA-APPROVED BIOMARKERS FOR DIFFERENT TYPES OF CANCER 45
TABLE 5 EMERGING ECONOMIES PRESENT SIGNIFICANT GROWTH OPPORTUNITIES 46
TABLE 6 PROVING THE CLINICAL VALIDITY and UTILITY OF BIOMARKER-BASED TESTS IS A MAJOR CHALLENGE FOR MARKET PLAYERS 47
TABLE 7 BIOMARKERS MARKET SIZE, BY PRODUCT, 2013-2020 ($BILLION) 50
TABLE 8 BIOMARKER CONSUMABLES MARKET, BY REGION, 2013-2020 ($BILLION) 51
TABLE 9 NORTH AMERICA: BIOMARKER CONSUMABLES MARKET, BY REGION,
2013-2020 ($BILLION) 52
TABLE 10 BIOMARKER SERVICES MARKET, BY REGION, 2013-2020 ($BILLION) 53
TABLE 11 NORTH AMERICA: BIOMARKER SERVICES MARKET, BY REGION,
2013-2020 ($BILLION) 53
TABLE 12 BIOMARKER SOFTWARE MARKET, BY REGION, 2013-2020 ($BILLION) 55
TABLE 13 NORTH AMERICA: BIOMARKER SOFTWARE MARKET, BY REGION,
2013-2020 ($MILLION) 55
TABLE 14 BIOMARKERS MARKET SIZE, BY TYPE, 2013-2020 ($BILLION) 58
TABLE 15 SAFETY BIOMARKERS MARKET SIZE, BY REGION, 2013-2020 ($BILLION) 59
TABLE 16 NORTH AMERICA: SAFETY BIOMARKERS MARKET, BY COUNTRY,
2013-2020 ($BILLION) 59
TABLE 17 EFFICACY BIOMARKERS MARKET SIZE, BY TYPE, 2013-2020 ($BILLION) 61
TABLE 18 EFFICACY BIOMARKERS MARKET SIZE, BY REGION, 2013-2020 ($BILLION) 62
TABLE 19 NORTH AMERICA: EFFICACY BIOMARKERS MARKET SIZE, BY COUNTRY,
2013-2020 ($BILLION) 62
TABLE 20 PREDICTIVE BIOMARKERS MARKET SIZE, BY REGION, 2013-2020 ($BILLION) 64
TABLE 21 NORTH AMERICA: PREDICTIVE BIOMARKERS MARKET SIZE, BY COUNTRY,
2013-2020 ($MILLION) 64
TABLE 22 SURROGATE BIOMARKERS MARKET SIZE, BY REGION, 2013-2020 ($BILLION) 65
TABLE 23 NORTH AMERICA: SURROGATE BIOMARKERS MARKET SIZE,
BY COUNTRY, 2013-2020 ($BILLION) 65
TABLE 24 PHARMACODYNAMIC BIOMARKERS MARKET SIZE, BY REGION,
2013-2020 ($BILLION) 67
TABLE 25 NORTH AMERICA: PHARMACODYNAMIC BIOMARKERS MARKET SIZE,
BY COUNTRY, 2013-2020 ($BILLION) 67
TABLE 26 PROGNOSTIC BIOMARKERS MARKET SIZE, BY REGION, 2013-2020 ($BILLION) 68
TABLE 27 NORTH AMERICA: PROGNOSTIC BIOMARKERS MARKET SIZE, BY COUNTRY,
2013-2020 ($BILLION) 68
TABLE 28 VALIDATION BIOMARKERS MARKET SIZE, BY REGION, 2013-2020 ($BILLION) 69
TABLE 29 NORTH AMERICA: VALIDATION BIOMARKERS MARKET SIZE, BY COUNTRY,
2013-2020 ($BILLION) 70
TABLE 30 BIOMARKERS MARKET SIZE, BY APPLICATION, 2013-2020 ($BILLION) 73
TABLE 31 DIAGNOSTICS DEVELOPMENT MARKET SIZE, BY REGION, 2013-2020 ($BILLION) 74
TABLE 32 NORTH AMERICA: DIAGNOSTICS DEVELOPMENT MARKET SIZE,
BY COUNTRY, 2013-2020 ($BILLION) 74
TABLE 33 DRUG DISCOVERY AND DEVELOPMENT MARKET SIZE, BY REGION,
2013-2020 ($BILLION) 76
TABLE 34 NORTH AMERICA: DRUG DISCOVERY AND DEVELOPMENT MARKET SIZE,
BY COUNTRY, 2013-2020 ($BILLION) 76
TABLE 35 PERSONALIZED MEDICINE MARKET SIZE, BY REGION, 2013-2020 ($BILLION) 77
TABLE 36 NORTH AMERICA: PERSONALIZED MEDICINE MARKET SIZE, BY COUNTRY,
2013-2020 ($BILLION) 78
TABLE 37 DISEASE RISK ASSESSMENT MARKET SIZE, BY REGION, 2013-2020 ($BILLION) 79
TABLE 38 NORTH AMERICA: DISEASE RISK ASSESSMENT MARKET SIZE, BY COUNTRY, 2013-2020 ($BILLION) 79
TABLE 39 BIOMARKERS MARKET SIZE FOR OTHER APPLICATIONS, BY REGION,
2013-2020 ($BILLION) 81
TABLE 40 NORTH AMERICA: BIOMARKERS MARKET SIZE FOR OTHER APPLICATIONS,
BY COUNTRY, 2013-2020 ($BILLION) 81
TABLE 41 BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2013-2020 ($BILLION) 84
TABLE 42 KEY CANCER BIOMARKERS IN CLINICAL USE 84
TABLE 43 ASIA TO BE THE FASTEST-GROWING REGIONAL SEGMENT FOR THE CANCER DISEASE INDICATION SEGMENT 85
TABLE 44 BIOMARKERS MARKET SIZE FOR CANCER, BY REGION, 2013-2020 ($BILLION) 85
TABLE 45 NORTH AMERICA: BIOMARKERS MARKET SIZE FOR CANCER, BY REGION,
2013-2020 ($BILLION) 86
TABLE 46 CARDIOVASCULAR DISORDER BIOMARKERS 86
TABLE 47 BIOMARKERS MARKET SIZE FOR CARDIOVASCULAR DISORDERS, BY REGION, 2013-2020 ($BILLION) 87
TABLE 48 NORTH AMERICA: BIOMARKERS MARKET SIZE FOR CARDIOVASCULAR DISORDERS, BY REGION, 2013-2020 ($BILLION) 88
TABLE 49 BIOMARKERS MARKET SIZE FOR NEUROLOGICAL DISORDERS, BY REGION,
2013-2020 ($BILLION) 89
TABLE 50 NORTH AMERICA: BIOMARKERS MARKET SIZE FOR NEUROLOGICAL DISORDERS, BY REGION, 2013-2020 ($BILLION) 90
TABLE 51 BIOMARKERS FOR IMMUNOLOGICAL DISEASES 90
TABLE 52 BIOMARKERS MARKET SIZE FOR IMMUNOLOGICAL DISORDERS, BY REGION, 2013-2020 ($BILLION) 91
TABLE 53 NORTH AMERICA: BIOMARKERS MARKET SIZE FOR IMMUNOLOGICAL DISORDERS, BY REGION, 2013-2020 ($BILLION) 92
TABLE 54 BIOMARKERS FOR RENAL DISORDERS 92
TABLE 55 BIOMARKERS MARKET SIZE FOR OTHER DISEASE INDICATIONS, BY REGION, 2013-2020 ($BILLION) 93
TABLE 56 NORTH AMERICA: BIOMARKERS MARKET SIZE FOR OTHER DISEASE INDICATIONS, BY REGION, 2013-2020 ($BILLION) 94
TABLE 57 BIOMARKERS MARKET SIZE, BY REGION, 2013-2020 ($BILLION) 97
TABLE 58 NORTH AMERICA: BIOMARKERS MARKET SIZE, BY COUNTRY,
2013-2020 ($BILLION) 101
TABLE 59 NORTH AMERICA: BIOMARKERS MARKET SIZE, BY PRODUCT,
2013-2020 ($BILLION) 101
TABLE 60 NORTH AMERICA: BIOMARKERS MARKET SIZE, BY TYPE, 2013-2020 ($BILLION) 102
TABLE 61 NORTH AMERICA: EFFICACY BIOMARKERS MARKET SIZE, BY TYPE,
2013-2020 ($BILLION) 103
TABLE 62 NORTH AMERICA: BIOMARKERS MARKET SIZE, BY APPLICATION,
2013-2020 ($BILLION) 104
TABLE 63 NORTH AMERICA: BIOMARKERS MARKET SIZE, BY DISEASE INDICATION,
2013-2020 ($BILLION) 105
TABLE 64 U.S.: BIOMARKERS MARKET SIZE, BY PRODUCT, 2013-2020 ($BILLION) 107
TABLE 65 U.S.: BIOMARKERS MARKET SIZE, BY TYPE, 2013-2020 ($BILLION) 108
TABLE 66 U.S.: EFFICACY BIOMARKERS MARKET SIZE, BY TYPE, 2013-2020 ($BILLION) 109
TABLE 67 U.S.: BIOMARKERS MARKET SIZE, BY APPLICATION, 2013-2020 ($BILLION) 110
TABLE 68 U.S.: BIOMARKERS MARKET SIZE, BY DISEASE INDICATION,
2013-2020 ($BILLION) 111
TABLE 69 CANADA: BIOMARKERS MARKET SIZE, BY PRODUCT, 2013-2020 ($BILLION) 113
TABLE 70 CANADA: BIOMARKERS MARKET SIZE, BY TYPE, 2013-2020 ($BILLION) 114
TABLE 71 CANADA: EFFICACY BIOMARKERS MARKET SIZE, BY TYPE, 2013-2020 ($BILLION) 115
TABLE 72 CANADA: BIOMARKERS MARKET SIZE, BY APPLICATION, 2013-2020 ($BILLION) 116
TABLE 73 CANADA: BIOMARKERS MARKET SIZE, BY DISEASE INDICATION,
2013-2020 ($BILLION) 117
TABLE 74 EUROPE: BIOMARKERS MARKET SIZE, BY PRODUCT, 2013-2020 ($BILLION) 119
TABLE 75 EUROPE: BIOMARKERS MARKET SIZE, BY TYPE, 2013-2020 ($BILLION) 120
TABLE 76 EUROPE: EFFICACY BIOMARKERS MARKET SIZE, BY TYPE, 2013-2020 ($BILLION) 121
TABLE 77 EUROPE: BIOMARKERS MARKET SIZE, BY APPLICATION, 2013-2020 ($BILLION) 122
TABLE 78 EUROPE: BIOMARKERS MARKET SIZE, BY DISEASE INDICATION,
2013-2020 ($BILLION) 123
TABLE 79 ASIA: BIOMARKERS MARKET SIZE, BY PRODUCT, 2013-2020 ($BILLION) 126
TABLE 80 ASIA: BIOMARKERS MARKET SIZE, BY TYPE, 2013-2020 ($BILLION) 127
TABLE 81 ASIA: EFFICACY BIOMARKERS MARKET SIZE, BY TYPE, 2013-2020 ($BILLION) 128
TABLE 82 ASIA: BIOMARKERS MARKET SIZE, BY APPLICATION, 2013-2020 ($BILLION) 129
TABLE 83 ASIA: BIOMARKERS MARKET SIZE, BY DISEASE INDICATION,
2013-2020 ($BILLION) 130
TABLE 84 ROW: BIOMARKERS MARKET SIZE, BY PRODUCT, 2013-2020 ($BILLION) 132
TABLE 85 ROW: BIOMARKERS MARKET SIZE, BY TYPE, 2013-2020 ($BILLION) 133
TABLE 86 ROW: EFFICACY BIOMARKERS MARKET SIZE, BY TYPE, 2013-2020 ($BILLION) 134
TABLE 87 ROW: BIOMARKERS MARKET SIZE, BY APPLICATION, 2013-2020 ($BILLION) 135
TABLE 88 ROW: BIOMARKERS MARKET SIZE, BY DISEASE INDICATION,
2013-2020 ($BILLION) 136
TABLE 89 MARKET DEVELOPMENTS BETWEEN JANUARY 2012 AND MAY 2015 140
TABLE 90 ACQUISITION, 2012-2015 141
TABLE 91 AGREEMENT, COLLABORATIONS, EXPANSION, JOINT VENTURES AND PARTNERSHIPS, 2012-2015 142
TABLE 92 NEW PRODUCT AND SERVICE LAUNCHES, 2012-2015 143
TABLE 93 OTHER DEVELOPMENTS, 2012-2015 144


LIST OF FIGURES

FIGURE 1 BIOMARKERS MARKET 18
FIGURE 2 RESEARCH DESIGN 20
FIGURE 3 MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP APPROACH 22
FIGURE 4 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 22
FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 23
FIGURE 6 DATA TRIANGULATION METHODOLOGY 24
FIGURE 7 BIOMARKERS MARKET SIZE, BY PRODUCT, 2015 VS. 2020 ($BILLION) 28
FIGURE 8 BIOMARKERS MARKET SIZE, BY TYPE, 2015 VS. 2020 ($BILLION) 28
FIGURE 9 BIOMARKERS MARKET SIZE, BY APPLICATION, 2015 VS. 2020 ($BILLION) 29
FIGURE 10 BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2015 VS. 2020 ($BILLION) 29
FIGURE 11 BIOMARKERS MARKET SIZE, BY REGION, 2015 VS. 2020 ($BILLION) 30
FIGURE 12 GLOBAL BIOMARKERS MARKET TO WITNESS HIGH GROWTH DURING THE FORECAST PERIOD 31
FIGURE 13 CONSUMABLES SEGMENT TO ACCOUNT FOR THE LARGEST MARKET SHARE IN 2015 32
FIGURE 14 ASIA TO WITNESS HIGHEST GROWTH RATE IN THE FORECAST PERIOD 32
FIGURE 15 ASIAN MARKET SHOWS LUCRATIVE GROWTH OPPORTUNITIES 33
FIGURE 16 BIOMARKERS MARKET: BY PRODUCT 35
FIGURE 17 BIOMARKERS MARKET: BY TYPE 35
FIGURE 18 BIOMARKERS MARKET: BY APPLICATION 36
FIGURE 19 BIOMARKERS MARKET: BY DISEASE INDICATION 36
FIGURE 20 BIOMARKERS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 37
FIGURE 21 INCREASING HEALTHCARE EXPENDITURE IS THE MOST IMPORTANT DRIVER FOR THE BIOMARKERS MARKET 38
FIGURE 22 INCREASING RandD INVESTMENTS BOOSTING GROWTH IN THE BIOMARKERS MARKET 39
FIGURE 23 BIOMARKERS MARKET, BY PRODUCT 49
FIGURE 24 CONSUMABLES SEGMENT TO COMMAND THE LARGEST SHARE OF THE BIOMARKERS MARKET IN 2015 49
FIGURE 25 NORTH AMERICA WILL BE THE LARGEST REGIONAL SEGMENT OF THE CONSUMABLES MARKET IN 2015 51
FIGURE 26 ASIA TO BE THE FASTEST-GROWING REGIONAL SEGMENT OF THE BIOMARKER SERVICES MARKET BETWEEN 2015 AND 2020 53
FIGURE 27 NORTH AMERICA TO COMMAND THE LARGEST SHARE OF THE BIOMARKER SOFTWARE MARKET IN 2015 54
FIGURE 28 BIOMARKERS MARKET, BY TYPE 57
FIGURE 29 SAFETY BIOMARKERS TO COMMAND THE LARGEST SHARE OF THE BIOMARKERS MARKET IN 2015 57
FIGURE 30 ASIA TO BE THE FASTEST-GROWING REGIONAL SEGMENT FOR SAFETY BIOMARKERS IN THE FORECAST PERIOD 59
FIGURE 31 EFFICACY BIOMARKERS MARKET, BY TYPE 60
FIGURE 32 PREDICTIVE BIOMARKERS SEGMENT TO COMMAND THE LARGEST SHARE OF THE EFFICACY BIOMARKERS MARKET IN 2015 61
FIGURE 33 NORTH AMERICA TO BE THE LARGEST REGIONAL SEGMENT FOR EFFICACY BIOMARKERS IN 2015 62
FIGURE 34 ASIA TO BE THE FASTEST-GROWING REGIONAL SEGMENT OF THE PREDICTIVE BIOMARKERS MARKET BETWEEN 2015 AND 2020 63
FIGURE 35 NORTH AMERICA TO COMMAND THE LARGEST SHARE OF THE SURROGATE BIOMARKERS MARKET IN 2015 65
FIGURE 36 ASIA TO BE THE FASTEST-GROWING REGIONAL SEGMENT FOR PHARMACODYNAMIC BIOMARKERS IN THE FORECAST PERIOD 66
FIGURE 37 NORTH AMERICA TO BE THE LARGEST REGIONAL SEGMENT OF THE PROGNOSTIC BIOMARKERS MARKET IN 2015 68
FIGURE 38 ASIA TO BE THE FASTEST-GROWING REGIONAL SEGMENT FOR VALIDATION BIOMARKERS BETWEEN 2015 AND 2020 69
FIGURE 39 BIOMARKERS MARKET, BY APPLICATION 72
FIGURE 40 DIAGNOSTICS DEVELOPMENT TO COMMAND THE LARGEST SHARE OF THE BIOMARKERS MARKET IN 2015 72
FIGURE 41 NORTH AMERICA IS EXPECTED TO BE THE LARGEST REGIONAL MARKET FOR DIAGNOSTICS DEVELOPMENT 74
FIGURE 42 ASIA TO BE THE FASTEST-GROWING REGIONAL SEGMENT IN THE DRUG DISCOVERY AND DEVELOPMENT MARKET 75
FIGURE 43 NORTH AMERICA TO COMMAND THE LARGEST SHARE OF THE PERSONALIZED MEDICINE MARKET IN 2015 77
FIGURE 44 ASIA IS THE FASTEST-GROWING REGIONAL SEGMENT FOR DISEASE RISK ASSESSMENT 79
FIGURE 45 NORTH AMERICA TO COMMAND THE LARGEST SHARE OF THE BIOMARKERS MARKET FOR OTHER APPLICATIONS 80
FIGURE 46 BIOMARKERS MARKET, BY DISEASE INDICATION 83
FIGURE 47 CANCER WILL BE THE LARGEST DISEASE INDICATION SEGMENT OF THE BIOMARKERS MARKET IN 2015 83
FIGURE 48 NORTH AMERICA TO BE THE LARGEST REGIONAL SEGMENT FOR BIOMARKERS FOR CARDIOVASCULAR DISORDERS IN 2015 87
FIGURE 49 ASIAN BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS TO GROW AT THE HIGHEST RATE 89
FIGURE 50 NORTH AMERICA TO COMMAND THE LARGEST SHARE OF THE BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS IN 2015 91
FIGURE 51 ASIA TO BE THE FASTEST-GROWING REGIONAL SEGMENT OF THE BIOMARKERS MARKET FOR OTHER DISEASE INDICATIONS 93
FIGURE 52 GLOBAL ECONOMIC INDICATORS (2003-2012) 96
FIGURE 53 BIOMARKERS MARKET SIZE AND GROWTH RATE, BY REGION, 2015-2020 97
FIGURE 54 BIOMARKERS MARKET IN ASIA TO WITNESS HIGHEST GROWTH RATE FROM
2015 TO 2020 98
FIGURE 55 NORTH AMERICA: ECONOMIC INDICATORS (2003-2012) 99
FIGURE 56 NORTH AMERICA: MARKET SNAPSHOT 100
FIGURE 57 CONSUMABLES IS ESTIMATED TO BE THE LARGEST PRODUCT SEGMENT OF THE NORTH AMERICAN BIOMARKERS MARKET IN 2015 101
FIGURE 58 SAFETY BIOMARKERS TO COMMAND THE LARGEST SHARE OF THE NORTH AMERICAN BIOMARKERS MARKET BY 2020 102
FIGURE 59 PREDICTIVE BIOMARKERS SEGMENT WILL CONTINUE TO DOMINATE THE EFFICACY BIOMARKERS MARKET IN NORTH AMERICA 103
FIGURE 60 DIAGNOSTICS DEVELOPMENT SEGMENT TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICAN BIOMARKERS APPLICATIONS MARKET IN 2015 104
FIGURE 61 CANCER TO ACCOUNT FOR THE LARGEST DISEASE INDICATION SEGMENT OF THE NORTH AMERICAN BIOMARKERS MARKET IN 2015 105
FIGURE 62 U.S.: ECONOMIC INDICATORS (2003-2012) 106
FIGURE 63 CONSUMABLES TO ACCOUNT FOR THE LARGEST SHARE OF THE U.S. BIOMARKERS PRODUCTS MARKET IN 2015 107
FIGURE 64 SAFETY BIOMARKERS TO FORM THE LARGEST SEGMENT OF THE U.S. BIOMARKERS MARKET IN 2015 108
FIGURE 65 PREDICTIVE BIOMARKERS WILL CONTINUE TO DOMINATE THE EFFICACY BIOMARKERS MARKET IN THE U.S. 109
FIGURE 66 DIAGNOSTICS DEVELOPMENT TO COMMAND THE LARGEST SHARE OF THE U.S. BIOMARKERS APPLICATIONS MARKET IN 2015 110
FIGURE 67 CANCER TO FORM THE LARGEST DISEASE INDICATION SEGMENT OF THE U.S. BIOMARKERS MARKET IN 2015 111
FIGURE 68 CANADA: ECONOMIC INDICATORS (2003-2012) 112
FIGURE 69 CONSUMABLES TO ACCOUNT FOR THE LARGEST SEGMENT OF THE CANADIAN BIOMARKERS PRODUCTS MARKET IN 2015 113
FIGURE 70 SAFETY BIOMARKERS TO DOMINATE THE CANADIAN BIOMARKERS MARKET
BY 2020 114
FIGURE 71 PREDICTIVE BIOMARKERS WILL CONTINUE TO DOMINATE THE CANADIAN EFFICACY BIOMARKERS MARKET 115
FIGURE 72 DIAGNOSTICS DEVELOPMENT SEGMENT TO ACCOUNT FOR THE LARGEST SHARE OF THE CANADIAN BIOMARKERS MARKET IN 2015 116
FIGURE 73 CANCER TO FORM THE LARGEST DISEASE INDICATION SEGMENT OF THE CANADIAN BIOMARKERS MARKET IN 2015 117
FIGURE 74 EUROPE: ECONOMIC INDICATORS (2003-2012) 118
FIGURE 75 CONSUMABLES IS ESTIMATED TO BE THE LARGEST PRODUCT SEGMENT OF THE EUROPEAN BIOMARKERS MARKET IN 2015 119
FIGURE 76 SAFETY BIOMARKERS TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPEAN BIOMARKERS MARKET IN 2015 120
FIGURE 77 PREDICTIVE BIOMARKERS TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPEAN EFFICACY BIOMARKERS MARKET IN 2015 121
FIGURE 78 DIAGNOSTICS DEVELOPMENT SEGMENT TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPEAN BIOMARKERS APPLICATIONS SEGMENT IN 2015 122
FIGURE 79 CANCER TO FORM THE LARGEST DISEASE INDICATION SEGMENT OF THE EUROPEAN BIOMARKERS MARKET IN 2015 123
FIGURE 80 ASIA: ECONOMIC INDICATORS (2003-2012) 124
FIGURE 81 ASIA: MARKET SNAPSHOT 125
FIGURE 82 CONSUMABLES IS ESTIMATED TO BE THE LARGEST SEGMENT OF THE ASIAN BIOMARKERS MARKET IN 2015 126
FIGURE 83 SAFETY BIOMARKERS TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIAN BIOMARKERS MARKET IN 2015 127
FIGURE 84 PREDICTIVE BIOMARKERS TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIAN EFFICACY BIOMARKERS MARKET IN 2015 128
FIGURE 85 DIAGNOSTICS DEVELOPMENT TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIAN BIOMARKERS APPLICATIONS MARKET IN 2015 129
FIGURE 86 CANCER TO FORM THE LARGEST DISEASE INDICATION SEGMENT OF THE ASIAN BIOMARKERS MARKET IN 2015 130
FIGURE 87 REST OF THE WORLD: ECONOMIC INDICATORS (2003-2012) 131
FIGURE 88 CONSUMABLES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ROW BIOMARKERS PRODUCTS MARKET IN 2015 132
FIGURE 89 SAFETY BIOMARKERS TO ACCOUNT FOR THE LARGEST SHARE OF THE ROW BIOMARKERS MARKET IN 2015 133
FIGURE 90 PREDICTIVE BIOMARKERS TO ACCOUNT FOR THE LARGEST SHARE OF THE ROW EFFICACY BIOMARKERS MARKET IN 2015 134
FIGURE 91 DIAGNOSTICS DEVELOPMENT TO ACCOUNT FOR THE LARGEST SHARE OF THE ROW BIOMARKERS APPLICATIONS MARKET IN 2015 135
FIGURE 92 CANCER TO FORM THE LARGEST DISEASE INDICATION SEGMENT OF THE ROW BIOMARKERS MARKET IN 2015 136
FIGURE 93 KEY DEVELOPMENTS WITHIN THE OVERALL BIOMARKERS MARKET,
2012 TO 2015 138
FIGURE 94 BIOMARKERS MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2014 139
FIGURE 95 FINANCIAL PERFORMANCE OF LEADING MARKET PLAYERS 145
FIGURE 96 COMPANY SNAPSHOT: QIAGEN N.V. 146
FIGURE 97 COMPANY SNAPSHOT: PERKINELMER, INC. 149
FIGURE 98 COMPANY SNAPSHOT: MERCK and CO, INC. 152
FIGURE 99 COMPANY SNAPSHOT: BIO-RAD LABORATORIES, INC. 154
FIGURE 100 COMPANY SNAPSHOT: ENZO BIOCHEM, INC. 156
FIGURE 101 COMPANY SNAPSHOT: EKF DIAGNOSTICS HOLDINGS, INC. 159

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Biobanking: Technologies and Global Markets

Biobanking: Technologies and Global Markets

  • $ 6650
  • Industry report
  • November 2016
  • by BCC Research

Use this report to: - Analyze the role biobanks play in the development of new drugs for specific disease treatments. - Learn about the prevailing market size for certain biobank services available ...

Cardiac Biomarkers Market By Type, By Application, By End Use, By Region And Segment Forecasts to 2024

Cardiac Biomarkers Market By Type, By Application, By End Use, By Region And Segment Forecasts to 2024

  • $ 4950
  • Industry report
  • September 2016
  • by Grand View Research

The cardiac biomarkers market is expected to reach USD13.3 billion by 2024, according to a new report by Grand View Research, Inc. The cardiac biomarkers market is anticipated to witness a lucrative growth ...

Cancer Biomarkers - Global Market Outlook (2016-2022)

Cancer Biomarkers - Global Market Outlook (2016-2022)

  • $ 4157
  • Industry report
  • October 2016
  • by Stratistics MRC

According to Stratistics MRC, the Global Cancer Biomarkers market is estimated at $9215.32 million in 2015 and is expected to reach $20958.63 million by 2022 growing at a CAGR of 12.5% from 2015 to 2022. ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.